Bioanalysis

  • Bioanalysis
  • The Altascientist—Scientific Journal on Recent LC-MS/MS Innovations (includes six case studies!)

    In this issue of The Altascientist, we cover the innovative progress we have recently seen in mass spectrometry, and how the advancements of science and technology can help you achieve critical milestones in your early phase drug development study or program.

    In this issue you will explore:

    • The case for stable isotope labelled internal standards for LC-MS quantitation
    • Recent innovations in mass spectrometry
    • Six case studies

    You may also be interested in the following:

    WRIB 2022 Poster Presentation: Development of Surrogate CSF for Quantitative Analysis of ASOs by Hybridization LC-MS/MS

    Webinars:

    Podcast: Microsampling: When Small Steps Lead to Big Outcomes

    Ophthalmic End-to-End Drug Development Solutions

    Customized Sample Collection Kits and Lab Manual Services

    Did you know that Altasciences’ Material Management Team has over 25 years of experience? Indeed, our experts in sample management processes have been supporting clinical trials worldwide for over two decades.

    We have designed an efficient system for accurate and safe clinical sample preparation, collection, and shipment from trial sites to bioanalytical laboratories.

    You may also be interested in the following:

    Quality is OUR Priority

    Our Laboratory Sciences Compliance Group is focused on quality, as well as on delivering critical drug biomarker quantitation data throughout each drug development phase.

    We provide you with:

    • Regulated bioanalysis across a wide range of analytes, including small molecules, biologics, bioequivalence, bioavailability, drug to drug interaction studies, and oligonucleotides 
    • Process audits and facility inspections
    • Quality management systems
    • RQAP-GLP Registered Auditors actively involved in the U.S. and Canadian regulatory communities (SQA, PRCSQA, CCSQA) 
    • Risk assessment quality audit plans
    • On-site inspections and study-specific audits
    • In-house Regulatory Team to ensure trials are conducted per protocol and within ICH/GCP/CFR guidelines  
    • Vendor qualifications
    • SOP management
    • GLP recognition-compliant archiving

    You may also be interested in the following:

    Join Dr. Kaylyn Koenig, on November 30th, for a conversation about digital droplet PCR (ddPCR) in preclinical research, including how it compares to qPCR.
     

    Register Now

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.​​​​

    Bioanalytical Speed and Quality Without Compromise

    We take meeting your timelines very seriously. Our operators and analysts have a breadth of experience and knowledge, and are dedicated to ensuring your samples are processed with the utmost efficiency.

    Our leading-edge labs include capabilities in flow cytometry, ligand binding and LC-MS/MS, supported by dedicated technicians.

    In this Quick Chat, Frédéric Massé, Senior Director, Bioanalytical Operations, and Mathieu Saulnier, Senior Director, Technical Support, discuss our continuous improvement culture, equipment optimization teams, and how their collaborative expertise benefits your programs.

    Watch Video

    Altasciences has been delivering excellence in bioanalytical services for over 25 years, and is fully equipped to analyze a comprehensive range of biomarkers to support your nonclinical toxicology programs. With over 260 scientists working in state-of-the-art laboratories and shifts running 24/7, as needed, our laboratory teams are able to process as many as 60,000 samples per month.

    You may also be interested in the following:

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    PCR testing continues to be in the spotlight as a reliable way of screening for COVID-19 and other viruses in patients. Its amplification process enables it to detect small portions of genetic material in these viruses. But PCR can be also used for a broad range of additional applications.

    Immunogenicity Target Interference: A Novel Blocking Approach

    Cell-based assays are usually used to represent the mechanism of action (MoA) of the administered drug. Throughout various stages of drug development, they may be used for different purposes. These include detecting the presence of neutralizing antibodies (NAbs) and evaluating a drug’s potency. In Altasciences’ webinar, “Development of a Cell-Based Assay,” Dr.

    Development of a Surrogate Cerebrospinal Fluid Matrix for Quantitative Analysis of Antisense Oligonucleotides by Hybridization LC-MS/MS

    Subscribe to Bioanalysis